115 related articles for article (PubMed ID: 17694704)
1. Pompholyx induced by intravenous immunoglobulin therapy.
Llombart M; García-Abujeta JL; Sánchez-Pérez RM; Hernando de Larramendi C
J Investig Allergol Clin Immunol; 2007; 17(4):277-8. PubMed ID: 17694704
[No Abstract] [Full Text] [Related]
2. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
Shiraishi T; Yamamoto T
Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
[TBL] [Abstract][Full Text] [Related]
3. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome.
Rhee DY; Park GH; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
J Eur Acad Dermatol Venereol; 2009 May; 23(5):602-4. PubMed ID: 18761548
[No Abstract] [Full Text] [Related]
4. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
5. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease.
Iannaccone S; Sferrazza B; Quattrini A; Smirne S; Ferini-Strambi L
Neurology; 1999 Sep; 53(5):1154-5. PubMed ID: 10496291
[No Abstract] [Full Text] [Related]
6. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.
Brazzelli V; Grassi S; Savasta S; Ruffinazzi G; Carugno A; Barbaccia V; Marseglia GL; Borroni G
Int J Immunopathol Pharmacol; 2014; 27(1):127-30. PubMed ID: 24674688
[TBL] [Abstract][Full Text] [Related]
7. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy.
Uyttendaele H; Obadiah J; Grossman M
J Drugs Dermatol; 2003 Jun; 2(3):337-41. PubMed ID: 12848120
[TBL] [Abstract][Full Text] [Related]
8. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome.
Young PK; Ruggeri SY; Galbraith S; Drolet BA
Arch Dermatol; 2006 Feb; 142(2):247-8. PubMed ID: 16490861
[No Abstract] [Full Text] [Related]
9. Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease.
Yokoyama K; Yoshida A
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30902846
[No Abstract] [Full Text] [Related]
10. Dyshidrotic eczema following intravenous immunoglobulin treatment.
Lee KC; Ladizinski B
CMAJ; 2013 Aug; 185(11):E530. PubMed ID: 23209117
[No Abstract] [Full Text] [Related]
11. Pompholyx as a side effect of intravenous immunoglobulin (IVIg).
Doyle C; Eustace K
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35354565
[TBL] [Abstract][Full Text] [Related]
12. Dyshidrotic eczema and seborrheic dermatitis-like eczematous eruption following intravenous immunoglobulin therapy.
Takci Z; Guler Simsek G; Uzuner H; Akbayrak A; Yıldız Seckin H; Karadag AS
Dermatol Ther; 2020 Nov; 33(6):e14147. PubMed ID: 32767429
[TBL] [Abstract][Full Text] [Related]
13. Dyshidrotic eczema associated with the use of IVIg.
Kotan D; Erdem T; Acar BA; Boluk A
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417935
[TBL] [Abstract][Full Text] [Related]
14. Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Kurata M; Horie C; Kano Y; Shiohara T
Br J Dermatol; 2016 Mar; 174(3):681-3. PubMed ID: 26412450
[No Abstract] [Full Text] [Related]
15. [Monthly low-dose immunoglobulin infusion as a maintenance therapy for multifocal motor neuropathy may reduce allergic adverse effects: a case report].
Murata Y; Okamoto T; Kondo Y; Chihara N; Furusawa Y; Murata M
Rinsho Shinkeigaku; 2010 Aug; 50(8):561-5. PubMed ID: 20803965
[TBL] [Abstract][Full Text] [Related]
16. Dyshydrotic Eczema Secondary to Intravenous Immunoglobulin Infusion: A Report of 2 Cases.
Garrido-Ríos AA; Martínez-Morán C; Borbujo J
Actas Dermosifiliogr; 2016 Jun; 107(5):431-3. PubMed ID: 26768317
[No Abstract] [Full Text] [Related]
17. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
[TBL] [Abstract][Full Text] [Related]
18. A 3-year causative study of pompholyx in 120 patients.
Guillet MH; Wierzbicka E; Guillet S; Dagregorio G; Guillet G
Arch Dermatol; 2007 Dec; 143(12):1504-8. PubMed ID: 18086998
[TBL] [Abstract][Full Text] [Related]
19. Delayed eczematous skin reaction as an adverse drug reaction to immunoglobulin infusions: A case series.
Barthel C; Musquer M; Veyrac G; Bernier C
Ann Dermatol Venereol; 2022 Dec; 149(4):264-270. PubMed ID: 35753818
[TBL] [Abstract][Full Text] [Related]
20. Pompholyx: a still unresolved kind of eczema.
Crosti C; Lodi A
Dermatology; 1993; 186(4):241-2. PubMed ID: 8513186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
